Amitriptyline Should Be Avoided in This Patient
Amitriptyline is contraindicated in patients with cardiovascular disorders and should not be used in this patient with dilated cardiomyopathy and an ejection fraction of 44%. The FDA label explicitly warns that patients with cardiovascular disorders should be "watched closely" and that tricyclic antidepressants "have been reported to produce arrhythmias, sinus tachycardia, and prolongation of the conduction time" 1. More critically, the drug has documented myocardial depressant effects even on healthy hearts.
Key Safety Concerns
Direct Myocardial Depression
Research demonstrates that amitriptyline exerts a depressant effect even on healthy myocardium 2. In a study of patients without cardiovascular disease, amitriptyline at therapeutic doses caused significant reduction in ejection fraction during stress testing (from 70.6% to 66.4%, p<0.001), revealing latent myocardial contractility depression that becomes clinically evident under stress 2. Your patient already has compromised cardiac function (EF 44%), placing them at substantially higher risk.
Documented Cardiotoxicity
A case report documents amitriptyline-induced myocarditis with pericardial involvement in a young patient with no previous cardiac history, resulting in an EF drop to 45% 3. This demonstrates the drug's potential for direct cardiac toxicity beyond its well-known effects on cardiac conduction.
Arrhythmia Risk
The FDA label warns of multiple cardiac conduction abnormalities including:
- QRS prolongation
- QTc prolongation
- Sinus tachycardia
- Ventricular arrhythmias
- Risk of sudden cardiac death in overdose 1
Clinical Context
Your patient has an EF of 44%, which falls into the heart failure with mildly reduced ejection fraction (HFmrEF) category per current AHA/ACC/HFSA guidelines 4. This population requires:
- Continuation of guideline-directed medical therapy (GDMT)
- Avoidance of medications that further depress myocardial function
- Close monitoring for progression to HFrEF (EF <40%)
The FDA specifically states that amitriptyline should be used "with caution in patients with cardiovascular disorders" and notes that "myocardial infarction and stroke have been reported with drugs of this class" 1.
Alternative Approach
Choose a different antidepressant class entirely. SSRIs or SNRIs have significantly safer cardiac profiles and do not carry the myocardial depressant effects or conduction abnormalities associated with tricyclic antidepressants. If a tricyclic is absolutely necessary for specific indications (such as neuropathic pain), cardiology consultation is mandatory before initiation, with baseline ECG, close monitoring, and consideration of the patient's overall cardiac risk profile.
The combination of pre-existing reduced ejection fraction, documented myocardial depressant effects at therapeutic doses, and FDA warnings against use in cardiovascular disease makes amitriptyline an inappropriate choice for this patient.